Cendakimab, a monoclonal antibody against interleukin-13, has shown improvement in oesophageal eosinophilia and endoscopic findings of EoE by EREFS, as well as a trend towards symptomatic improvement, and remains under investigation in phase 3 clinical trials.15 The gene discussed is IL13; the disease is eosinophilic esophagitis.